Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
2.

Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Lameh J, McFarland K, Ohlsson J, Ek F, Piu F, Burstein ES, Tabatabaei A, Olsson R, Bradley SR, Bonhaus DW.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):313-23. doi: 10.1007/s00210-011-0702-2. Epub 2011 Nov 15.

PMID:
22083558
3.

Neuropeptide FF receptors have opposing modulatory effects on nociception.

Lameh J, Bertozzi F, Kelly N, Jacobi PM, Nguyen D, Bajpai A, Gaubert G, Olsson R, Gardell LR.

J Pharmacol Exp Ther. 2010 Jul;334(1):244-54. doi: 10.1124/jpet.109.164384. Epub 2010 Mar 30.

PMID:
20354177
4.

Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.

Davis CN, Bradley SR, Schiffer HH, Friberg M, Koch K, Tolf BR, Bonhaus DW, Lameh J.

BMC Pharmacol. 2009 Dec 2;9:14. doi: 10.1186/1471-2210-9-14.

5.

AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW.

Neuropharmacology. 2010 Feb;58(2):365-73. doi: 10.1016/j.neuropharm.2009.10.003. Epub 2009 Oct 14.

PMID:
19835892
6.

Discovery of selective nonpeptidergic neuropeptide FF2 receptor agonists.

Gaubert G, Bertozzi F, Kelly NM, Pawlas J, Scully AL, Nash NR, Gardell LR, Lameh J, Olsson R.

J Med Chem. 2009 Nov 12;52(21):6511-4. doi: 10.1021/jm9011998.

PMID:
19803524
7.

Identification and characterization of novel small-molecule protease-activated receptor 2 agonists.

Gardell LR, Ma JN, Seitzberg JG, Knapp AE, Schiffer HH, Tabatabaei A, Davis CN, Owens M, Clemons B, Wong KK, Lund B, Nash NR, Gao Y, Lameh J, Schmelzer K, Olsson R, Burstein ES.

J Pharmacol Exp Ther. 2008 Dec;327(3):799-808. doi: 10.1124/jpet.108.142570. Epub 2008 Sep 3.

PMID:
18768780
8.

Identification of novel selective V2 receptor non-peptide agonists.

Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.

Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12.

PMID:
18761325
9.

Pharmacology of N-desmethylclozapine.

Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW.

Pharmacol Ther. 2007 Aug;115(2):223-31. Epub 2007 May 21. Review.

PMID:
17583355
10.

Transcutaneous blood gas CO2 monitoring of induced ventilatory depression in mice.

Sahbaie P, Modanlou S, Gharagozlou P, Clark JD, Lameh J, Delorey TM.

Anesth Analg. 2006 Sep;103(3):620-5. Erratum in: Anesth Analg. 2008 Apr;106(4):1325. Madanlou, Shohreh [corrected to Modanlou, Shohreh].

PMID:
16931671
11.

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.

J Pharmacol Exp Ther. 2006 May;317(2):910-8. Epub 2006 Feb 9.

PMID:
16469866
12.

Pharmacological profiles of opioid ligands at kappa opioid receptors.

Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J.

BMC Pharmacol. 2006 Jan 25;6:3.

13.

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR.

Psychopharmacology (Berl). 2004 Dec;177(1-2):207-16. Epub 2004 Jul 16.

PMID:
15258717
14.

Pharmacology of polymorphic variants of the human 5-HT1A receptor.

Del Tredici AL, Schiffer HH, Burstein ES, Lameh J, Mohell N, Hacksell U, Brann MR, Weiner DM.

Biochem Pharmacol. 2004 Feb 1;67(3):479-90.

PMID:
15037200
15.

Activity of opioid ligands in cells expressing cloned mu opioid receptors.

Gharagozlou P, Demirci H, David Clark J, Lameh J.

BMC Pharmacol. 2003 Jan 4;3:1. doi: 10.1186/1471-2210-3-1. Epub 2003 Jan 4.

16.

Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.

Gharagozlou P, Demirci H, Clark JD, Lameh J.

BMC Neurosci. 2002 Nov 18;3:19. Epub 2002 Nov 18.

17.

Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory.

DeLorey TM, Lin RC, McBrady B, He X, Cook JM, Lameh J, Loew GH.

Eur J Pharmacol. 2001 Aug 24;426(1-2):45-54.

PMID:
11525770
18.

Characterization of novel benzodiazepine ligands in Spodotera frugiperda (Sf-9) insect cells.

Lameh J, Keohane A, Clark DJ, Loew GH.

Neurosci Lett. 2001 Jun 22;306(1-2):25-8.

PMID:
11403949
19.

Characterization of benzodiazepine receptors in the cerebellum.

Lameh J, Wang P, Meredith D, Shafer SL, Loew GH.

Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):979-91.

PMID:
11041538
20.

Unraveling the identity of benzodiazepine binding sites in rat hipppocampus and olfactory bulb.

Lameh J, Wang P, Elgart D, Meredith D, Shafer SL, Loew GH.

Eur J Pharmacol. 2000 Jul 21;400(2-3):167-76.

PMID:
10988330
21.

Differential regulation of muscarinic M1 and M3 receptors by a putative phosphorylation domain.

Shockley MS, Tolbert LM, Tobin AB, Nahorski SR, Sadée W, Lameh J.

Eur J Pharmacol. 1999 Jul 14;377(1):137-46.

PMID:
10448936
22.
23.

Role of signal transduction in internalization of the G protein-coupled receptor for parathyroid hormone (PTH) and PTH-related protein.

Huang Z, Bambino T, Chen Y, Lameh J, Nissenson RA.

Endocrinology. 1999 Mar;140(3):1294-300.

PMID:
10067856
24.
25.
26.

A constitutively internalizing and recycling mutant of the mu-opioid receptor.

Segredo V, Burford NT, Lameh J, Sadée W.

J Neurochem. 1997 Jun;68(6):2395-404.

27.
28.

Human muscarinic cholinergic receptor Hm1 internalizes via clathrin-coated vesicles.

Tolbert LM, Lameh J.

J Biol Chem. 1996 Jul 19;271(29):17335-42.

29.

Agonist-induced internalization of human ml muscarinic receptor mutants: immunofluorescence confocal microscopy.

Arden J, Lameh J.

Proc West Pharmacol Soc. 1996;39:51-4. No abstract available.

PMID:
8895968
30.

Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells.

Arden JR, Segredo V, Wang Z, Lameh J, Sadée W.

J Neurochem. 1995 Oct;65(4):1636-45.

PMID:
7561859
31.

Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors.

Högger P, Shockley MS, Lameh J, Sadée W.

J Biol Chem. 1995 Mar 31;270(13):7405-10.

32.
33.

Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling.

Moro O, Lameh J, Högger P, Sadée W.

J Biol Chem. 1993 Oct 25;268(30):22273-6.

34.
35.

Mapping the ligand binding pocket of the human muscarinic cholinergic receptor Hm1: contribution of tyrosine-82.

Drübbisch V, Lameh J, Philip M, Sharma YK, Sadée W.

Pharm Res. 1992 Dec;9(12):1644-7.

PMID:
1488411
36.

Mutational analysis of third cytoplasmic loop domains in G-protein coupling of the HM1 muscarinic receptor.

Arden JR, Nagata O, Shockley MS, Philip M, Lameh J, Sadée W.

Biochem Biophys Res Commun. 1992 Nov 16;188(3):1111-5.

PMID:
1445347
37.

Interaction among mu-opioid receptors and alpha 2-adrenoceptors on SH-SY5Y human neuroblastoma cells.

Lameh J, Eiger S, Sadée W.

Eur J Pharmacol. 1992 Sep 1;227(1):19-24.

PMID:
1358661
38.

Hm1 muscarinic cholinergic receptor internalization requires a domain in the third cytoplasmic loop.

Lameh J, Philip M, Sharma YK, Moro O, Ramachandran J, Sadée W.

J Biol Chem. 1992 Jul 5;267(19):13406-12.

39.

Characterization of the RDC1 gene which encodes the canine homolog of a proposed human VIP receptor. Expression does not correlate with an increase in VIP binding sites.

Cook JS, Wolsing DH, Lameh J, Olson CA, Correa PE, Sadee W, Blumenthal EM, Rosenbaum JS.

FEBS Lett. 1992 Mar 30;300(2):149-52.

40.

125I-beta-endorphin binding to neuroblastoma X glioma NG108-15 cells: distribution of delta opioid receptors.

Cone RI, Rosenfeld S, Lameh J, Sadée W.

Life Sci. 1992;51(22):PL219-24.

PMID:
1331640
41.
42.

Structure and function of G protein coupled receptors.

Lameh J, Cone RI, Maeda S, Philip M, Corbani M, Nádasdi L, Ramachandran J, Smith GM, Sadée W.

Pharm Res. 1990 Dec;7(12):1213-21. Review.

PMID:
1965663
43.

Morphine impurity with opioid activity is identified as 10 alpha-hydroxymorphine.

Farsam H, Eiger S, Lameh J, Rezvani A, Gibson BW, Sadée W.

Pharm Res. 1990 Nov;7(11):1205-7. No abstract available.

PMID:
1963495
44.

Regulation of cyclic AMP by the mu-opioid receptor in human neuroblastoma SH-SY5Y cells.

Yu VC, Eiger S, Duan DS, Lameh J, Sadée W.

J Neurochem. 1990 Oct;55(4):1390-6.

PMID:
1697894
45.

Internalization of the Hm1 muscarinic cholinergic receptor involves the third cytoplasmic loop.

Maeda S, Lameh J, Mallet WG, Philip M, Ramachandran J, Sadée W.

FEBS Lett. 1990 Sep 3;269(2):386-8.

46.
47.
48.

Mechanistic studies on N-benzyladriamycin-14-valerate (AD 198), a highly lipophilic alkyl adriamycin analog.

Lameh J, Chuang LF, Israel M, Chuang RY.

Anticancer Res. 1988 Jul-Aug;8(4):689-93.

PMID:
3052250
49.

The inhibitory effect of rhodamine 123 on DNA and RNA synthesis of E. coli in vitro.

Lameh J, Chuang RY, Krag D, Chase D.

Proc West Pharmacol Soc. 1987;30:103-7. No abstract available.

PMID:
2442766

Supplemental Content

Support Center